Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell Limited has issued 1,455,911 fully paid ordinary shares following the exercise of unlisted options, allowing immediate trading under the Corporations Act exemption. This move reflects Orthocell’s strategic efforts to enhance its financial flexibility and support its ongoing product development and market expansion initiatives.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell is a regenerative medicine company specializing in products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for tissue reconstruction in dental and orthopedic applications, with products like Striate+™ and Remplir™ cleared for use in multiple countries. The company is also advancing its tendon cell therapy in the US, engaging with the FDA to facilitate market entry.
Average Trading Volume: 1,087,913
Technical Sentiment Signal: Buy
Current Market Cap: A$298.1M
See more data about OCC stock on TipRanks’ Stock Analysis page.